- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 10, Issue 26, 2004
Current Pharmaceutical Design - Volume 10, Issue 26, 2004
Volume 10, Issue 26, 2004
-
-
Identification and Validation of Novel Drug Targets in Tuberculosis
By K. DuncanThere is an urgent need for new antimycobacterial drugs, and in particular for novel agents that will shorten the duration of tuberculosis chemotherapy, or overcome drug-resistant strains of the causative organism, Mycobacterium tuberculosis. Our knowledge of the tubercle bacillus and its complex interaction with the human host has improved dramatically in recent years, particularly with the determination of its co Read More
-
-
-
Structural Bioinformatic Approaches to the Discovery of New Antimycobacterial Drugs
Authors: Katherine Kantardjieff and Bernhard RuppIntegrated bioinformatic approaches to drug discovery exploit computational techniques to examine the flow of information from genome to structure to function. Informatics is being be used to accelerate and rationalize the process of antimycobacterial drug discovery and design, with the immediate goals to identify viable drug targets and produce a set of critically evaluated protein target models and corresponding se Read More
-
-
-
Fluoroquinolones as Chemotherapeutics Against Mycobacterial Infections
More LessThe antimicrobial agents used in the treatment of mycobacterial infections have remained largely unchanged for several decades. Primary treatment of tuberculosis relies on four drugs, isoniazid, a rifamycin, pyrazinamide, and ethambutol (or streptomycin), and generally results in >95% cure in uncomplicated tuberculosis infection. Drug resistance greatly complicates treatment of this disease. Treatment of tubercu Read More
-
-
-
Effects of Macrolides and Ketolides on Mycobacterial Infections
Authors: Luiz E. Bermudez and Yoshitaka YamazakiNew macrolides, such as clarithromycin and azithromycin, are active agents to Mycobacterium avium complex (MAC). Both clarithromycin and azithromycin are well-known for the ability to improve the prognosis of AIDS patients with disseminated MAC infection. However, the administration of monotherapy with a macrolide is usually associated with the emergence of drug resistance after a few months of use. Therefore, the Read More
-
-
-
In Vitro and In Vivo Activities of New Rifamycin Derivatives Against Mycobacterial Infections
Authors: N. Lounis and G. RoscignoSeveral rifamycin derivatives have been developed during the last 15 years for the treatment of mycobacterial infections. For tuberculosis, rifabutin (RFB) showed strong activity and seemed to be suitable when tuberculosis patients were also treated for their AIDS infection. Rifapentine (RPT) was evaluated in patients with or without AIDS for its intermittent use. It displayed promising activity but must be strengthened in situations, Read More
-
-
-
Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Authors: Clifton E. Barry, Helena I.M. Boshoff and Cynthia S. DowdNitroaromatic antibiotics have a long and controversial history in human and veterinary medicine. This controversy lies behind the presumption of many pharmaceutical companies that nitroaromatic compounds should be filtered from the list of drug-like compounds but stands at odds with the remarkably safe clinical record of use of such compounds. In this review, we will describe the whole-cell structure-activity relationships t Read More
-
-
-
Liposome Technology for Drug Delivery Against Mycobacterial Infections
Authors: G. K. Khuller, Manisha Kapur and Sadhna SharmaMycobacteria are intracellular pathogens that invade and reside inside macrophages. There has been a rapid resurgence in infections caused by the genus mycobacteria. Chemotherapy of mycobacterial infections is prolonged, hepatotoxic and very often inadequate in achieving optimal drug concentrations inside the cells. Recent advances in controlled delivery systems for drugs such as liposomes have sparked a renewed int Read More
-
-
-
Microsphere Technology for Chemotherapy of Mycobacterial Infections
More LessThe purpose of this review article is to examine the various studies that have evaluated microspheres for delivery of antimycobacterial drugs. Some of the studies strictly involve the development and evaluation of microspheres for use in antimycobacterial drug delivery, whereas others actually use drug-loaded microspheres to treat mycobacterial infections in cell lines and small animals. Although there is a potential to u Read More
-
-
-
Predictive In Vitro Models of the Sterilizing Activity of Anti-Tuberculosis Drugs
Authors: Denis A. Mitchison and Anthony R.M. CoatesSterilizing drugs kill Mycobacterium tuberculosis that persists during chemotherapy. Predictive models should mimic the conditions causing persistence in the lesions of cavitary disease, and should grade current anti-tuberculosis drugs according to their sterilizing activity determined in clinical trials. Models should start with old, stationary cultures grown micro-aerophilically. In these, persistent bacilli occur in different po Read More
-
-
-
Adjunctive Immunotherapy of Mycobacterial Infections
More LessIn order to cope with the worldwide increase in the prevalence of multidrug-resistant tuberculosis and Mycobacterium avium complex (MAC) infections, a number of new antimycobacterial drugs have been or are being synthesized and developed. Development of new protocols for chemotherapy of refractory mycobacterioses is also sharing promise. In this context, one promising strategy is to devise regimens to tr Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
